Biotech company 10x Genomics (NASDAQ:TXG) reported Q1 CY2025 results , with sales up 9.8% year on year to $154.9 million. On ...

For the quarter ended March 2025, 10x Genomics (TXG) reported revenue of $154.88 million, up 9.8% over the same period last year. EPS came in at -$0.36, compared to -$0.50 in the year-ago quarter. The ...

PLEASANTON, Calif. (AP) — PLEASANTON, Calif. (AP) — 10x Genomics Inc. (TXG) on Thursday reported a loss of $34.4 million in its first quarter. The Pleasanton, California-based company said it had a ...

Long term investing works well, but it doesn't always work for each individual stock. We don't wish catastrophic capital loss on anyone. Imagine if you held 10x Genomics, Inc. (NASDAQ:TXG) for half a ...

Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the first ...

Why are tensions escalating between India and Pakistan? Our team of BBC experts explain, after India launches missile strikes in Pakistan and Pakistan-administered Kashmir. Five Indian jets were ...

Short interest in 10x Genomics Inc (NASDAQ:TXG) increased during the last reporting period, rising from 12.06M to 12.86M. This put 17.73% of the company's publicly available shares short.

Shares of TXG opened at $7.14 on Tuesday. 10x Genomics has a 1 year low of $6.78 and a 1 year high of $37.74. The stock’s fifty day moving average price is $10.96 and its two-hundred day moving ...

Genomics (TXG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.